Salix Pharmaceuticals (SLXP) announced Monday morning that rifaximin, versus placebo treated patients, demonstrated a statistically significant improvement for the primary endpoint of the adequate relief of IBS symptoms in two Phase 3 trials.
Salix Pharmaceuticals gapped open sharply higher Monday, but was range-bound for the majority of the session. The stock closed up by $6.84 at $20.22 on the highest volume of the year. Shares leaped to a new high for the year.
For comments and feedback: editorial@rttnews.com